marijuana stocks news

Form 8-K for LEXARIA CORP.


Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Stat

Securities Item 5.02. Appointment of Principal Officers.On December 22, 2014, the Company appointed Thomas Ihrke as Vice President of US Operations. The Company executed an eighteen month consulting contract with Mr. Ihrke with a monthly compensation of $3,000.

The Company on June 11, 2014 had adopted the 2014 Stock Option Plan. Based on this original Stock Option Plan, on December 22, 2014, the Company has granted 1,425,000 stock options to Directors, Officers and consultants. The exercise price of the stock options is $0.11, 1,125,000 vesting immediately, 100,000 vesting in six month, and 100,000 vesting in 12 months expiring on December 22, 2019.

The following are the recipients and the options granted:

                            Chris Bunka      500,000
                            Bal Bhullar      500,000
                            Nicholas Baxter  100,000
                            Thomas Ihrke     300,000

Allan Spissinger 25,000The securities referred to herein will not be and have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.


Item 7.01 Regulation FD Disclosure.A copy of the news release announcing the stock options and agreement is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.



Exhibit No. Description

  10.1        Form of Stock Option Agreement dated December 22, 2014
  10.2        Consulting Agreement with Thomas Ihrke
  99.1        Press Release dated December 22, 2014


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$CFA Holds Forum and Brainstorm on Africa Healthcare Infrastructure Challenges

Constituency for Africa Holds Forum and Brainstorm on Africa Healthcare Infrastructure Challenges…

GW Pharmaceuticals (GWPH) and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Meeting Highlights Include New Phase 3 Data for EPIDIOLEX in Tuberous Sclerosis…

Marijuana Stocks: Nabis Holdings, Inc. Interview and News from May 4, 2019 to June 3, 2019

The pre-recorded interview below took place on May 4, 2019, between Marijuana…